

Medication Adherence and Treatment Satisfaction in Chronic Obstructive Pulmonary Disease and Bronchial Asthma

Thesis

Submitted for Partial Fulfillment of Master
Degree in Chest Diseases and Tuberculosis

By

Abeer Abd El Zaher Abd El Azeem Nada
M.B, B.CH.

Under Supervision of

Professor. Yasser Mustafa Mohammed

Professor of Chest Diseases
Faculty of Medicine –Ain Shams University

Assistant Professor. Iman Hassan Galal

Assistant Professor of Chest Diseases
Faculty of Medicine –Ain Shams University

Faculty of Medicine
Ain Shams University
2013

﴿بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ﴾

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

البقرة آية ٣٢



ACKNOWLEDGMENT

First, thanks to *"ALLAH"* for granting me the power to accomplish this work and without His willing I would have achieved nothing.

I would like to express my sincere gratitude and appreciation to *Prof. Dr. Yasser Mustafa Mohammed*, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University for his valuable knowledge, great help, continuous guidance and kind encouragement during this work and reviewing my work till the end. Words of thanks are minute to express my gratitude for him for giving me the chance to learn something new and useful.

I would like to express my deepest thanks and gratitude to *Dr. Iman Hassan Galal*, Assistant Professor of Chest Diseases, Faculty of Medicine, and Ain Shams University for her guidance and support throughout this work.

Finally, I would like to express my deep thanks to *my family* who were always beside me giving me all forms of support to accomplish this work.

The candidate

Abeer Abd Elzaher Abd Elazeem

LIST OF Abbreviations

BLVR	Bronchoscopic Lung Volume Reduction
COPD	Chronic Obstructive Pulmonary Disease
CPAP	continuous positive airway pressure
CT	Computed tomography
FEV ₁	Forced Expiratory Volume in the first second
FEV ₁ /FVC	Forced Expiratory Volume in the first second/forced vital capacity
ICS	Inhaled corticosteroids
IgE	immunoglobulin E
kPa	a unit of pressure equal to 1000 pascals
LABA	Long Acting B ₂ Agonist
LTRA	Leukotriene receptor antagonist
LVRs	Lung Volume Reduction Surgery
MARS	Medication Adherence Report Scale
MDIs	Metered Dose Inhalers
MMAS	Morisky Medication Adherence Scale
mMRC	Modified Medical Research Council(dyspnea scale)
NIV	Non-invasive ventilation
PaO ₂	Partial pressure of oxygen in arterial blood.
PEF	Peak Expiratory Flow
VA/Q	Ventilation perfusion ratio
RV	Residual volume
SABA	Short Acting B ₂ Agonist
SaO ₂	percentage of oxygen saturation of arterial blood
TLC	Total lung capacity
TS-M	Treatment Satisfaction- Medication
TSQM	Treatment Satisfaction Questionnaire Medication
WHO	World Health Organization

LIST OF TABLES

Table No.	Title	Page
1	Differential Diagnosis of COPD	18
2	Differential Diagnosis of asthma	31
3	Demographic characteristics of COPD group	76
4	Pulmonary functions of COPD group	77
5	Destructive data of Treatment Satisfaction Questionnaire Medication Scale (TSQM) among COPD group	78
6	Descriptive data of Treatment Satisfaction Questionnaire Medication scale (TSQM) among COPD group	82
7	Destructive data of Morisky medication adherence (MMAS) among COPD group	83
8	Demographic characteristics of Asthma group	85
9	Pulmonary functions among Asthma group	86
10	Descriptive data of Treatment Satisfaction Questionnaire Medication Scale (TSQM) among Asthma group	87
11	Treatment Satisfaction Questionnaire Medication Scale (TSQM) among Asthma group	90
12	Morisky medication adherence scale (MMAS) among Asthma group	91
13	Socio-demographic distribution of all studied patients	93
14	Comparison between COPD and Asthma groups regarding demographic characteristics	94
15	Comparison between COPD and Asthma groups regarding pulmonary functions	98
16	Comparison between COPD and Asthma groups regarding Treatment Satisfaction Questionnaire Scale (TSQM)	100
17	Comparison between COPD and Asthma groups regarding MMAS	103

18	Comparison between males and females regarding scales	104
19	Comparison between smokers and non-smokers regarding scales	105
20	Comparison between recurrent and non-recurrent hospital admission regarding scales	106
21	Comparison between patients with co-morbidity and patients without co-morbidity regarding scales	107
22	Comparison between subjective regularity of treatment and subjective irregularity of treatment regarding scales	108
23	Comparison between subjective treatment satisfaction and subjective treatment dissatisfaction regarding scales	109
24	Correlation between scales and other factors COPD group	110
25	Correlation between scales and other factors asthma group	122
26	Regression analysis for factors affecting MMAS scale	128
27	Regression analysis for factors affecting TSQM global satisfaction scale	129
28	Regression analysis for factors affecting TSQM convenience scale	130
29	Regression analysis for factors affecting TSQM side	131
30	Regression analysis for factors affecting TSQM effectiveness scale	132

LIST OF FIGURES

Figure No.	Title	Page
1	spirometer (Micro lab)	65
2	Comparison between COPD and Asthma groups regarding sex, residence, recurrent hospital admission and co-morbidities	95
3	Comparison between COPD and Asthma groups regarding education and subjective regularity of treatment	96
4	Comparison between COPD and Asthma groups regarding occupation	96
5	Comparison between COPD and Asthma groups regarding by who treatment prescribed	97
6	Comparison between COPD and Asthma groups regarding x ray findings and smoking	97
7	Comparison between COPD and Asthma groups regarding pulmonary functions	99
8	Comparison between COPD and BA groups regarding bronchodilators reversibility test	99
9	Comparison between COPD and Asthma groups regarding TSQM subscales	102
10	Comparison between COPD and Asthma groups regarding adherence to medications	104
11	Correlation between TSQM-Global satisfaction and total MMAS (COPD group)	112
12	Correlation between TSQM-Side effect and TSQM-Convenience (COPD group)	112
13	Correlation between TSQM-Side effects and TSQM-Effectiveness (COPD group)	113
14	Correlation between TSQM-Convenience and Effectiveness (COPD group)	114
15	Correlation between TSQM-Global satisfaction and TSQM-Effectiveness (COPD group)	114

16	Correlation between TSQM-Global satisfaction and TSQM-Side effects (COPD group)	115
17	Correlation between TSQM-Global satisfaction and TSQM-Convenience (COPD group)	115
18	Correlation between total MMAS and TSQM-Convenience (COPD group)	116
19	Correlation between total MMAS and TSQM-Side effects (COPD group)	116
20	Correlation between total MMAS and TSQM-Effectiveness (COPD group)	117
21	Correlation between TSQM-Effectiveness and Age (COPD group)	117
22	Correlation between TSQM-Effectiveness and duration of chest medications (COPD group)	118
23	Correlation between TSQM-Effectiveness and duration of general medications (COPD group)	118
24	Correlation between TSQM-Side effects and FEV1/FVC% (COPD group)	119
25	Correlation between TSQM-Convenience and FEV1/FVC% (COPD group)	119
26	Correlation between TSQM-Convenience and duration of chest medications (COPD group)	120
27	Correlation between TSQM-Global satisfaction and duration of chest medications (COPD group)	120
28	Correlation between total MMAS and FEV1/FVC% (COPD group)	121
29	Correlation between total MMAS and cigarette smoking index (COPD group)	121
30	Correlation between TSQM-Global satisfaction and total MMAS (Asthma group)	123
31	Correlation between TSQM-Side effects and TSQM-Effectiveness (Asthma group)	123
32	Correlation between TSQM-Convenience and Effectiveness (Asthma group)	124
33	Correlation between TSQM-Global satisfaction and TSQM-Effectiveness (Asthma group)	124
34	Correlation between TSQM-Global satisfaction and TSQM-Side	125

	effects (Asthma group)	
35	Correlation between TSQM-Global satisfaction and TSQM-Convenience (Asthma group)	125
36	Correlation between total MMAS and TSQM-Convenience (Asthma group)	126
37	Correlation between total MMAS and TSQM-Side effects (Asthma group)	126
38	Correlation between total MMAS and TSQM-Effectiveness (Asthma group)	127
39	Correlation between TSQM-Side effect and TSQM-Convenience (asthma group)	127

LIST OF CONTENTS

Contents	Page
Introduction	1
Aim of the Work	3
Review of Literature	4
Chronic obstructive lung disease (COPD)	4
Bronchial asthma	27
Medication adherence	41
Treatment satisfaction	33
Treatment Satisfaction Questionnaire Medication (TSQM 1.4)	55
Morisky Medication Questionnaire Medication (MMAS)	59
Subjects and Methods	62
Results	76
Discussion	133
Summary	141
Conclusion	144
Recommendations	146
References	147
Arabic Summary	158

Introduction

Chronic obstructive pulmonary disease (COPD) is life-threatening lung disease. Although COPD is preventable and can be managed, it continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is currently the fourth leading cause of death worldwide and the WHO predicts it will rise to third leading cause by 2030.¹

Bronchial asthma is a chronic inflammatory disorder of airways. Chronically inflamed airways are hyper responsive, they become obstructed and airflow is limited when airways are exposed to various risk factors. Asthma causes episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning. Asthma is one of the most common chronic diseases with an estimated 300 million individuals affected worldwide.²

Asthma and COPD are long-term conditions requiring prolonged treatment. It is important that patients feel confident with the medication they are using and the treatment is adequate in controlling symptoms and side effects of treatment are minimal and well tolerated .If these conditions are not met, it is likely that patients will not comply with the prescribed treatment regimen.³

Treatment Adherence is defined as “the extent to which a person’s behavior (in terms of taking medications, following diets, or executing lifestyle changes) coincides with medical or health advice.”⁴

Adherence to treatment is one of the most important factors that guarantee the success of the COPD and asthma treatment. Several factors

may influence adherence to treatment in Asthma and COPD such as patients' knowledge about their disease, cultural and socioeconomic aspects, and poor perception of symptoms, adverse events, and skills in use inhaler devices. In addition, compliance with medical prescriptions tends to decline steeply over time.⁵

Also patient satisfaction is an important measure that should be included in healthcare evaluations, it is important to know how patients feel about treatment regimens actually adopted. Such information may assist the definition of optimal medical care for the individual patient.⁶

Aim of Work

The purpose of the present study is to assess the medication adherence and treatment satisfaction among some Egyptian patients with chronic obstructive pulmonary disease and bronchial asthma.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and co-morbidities contribute to the overall severity in individual patients. The chronic airflow limitation characteristic of COPD is caused by a mixture of small airways disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person. Chronic inflammation causes structural changes and narrowing of the small airways. Destruction of the lung parenchyma, also by inflammatory processes, leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil, in turn; these changes diminish the ability of the airways to remain open during expiration. Airflow limitation is best measured by spirometry, as this is the most widely available, reproducible test of lung function.⁷

Only one of several structural abnormalities present in patients with COPD. Chronic bronchitis, or the presence of cough and sputum production for at least 3 months each of two consecutive years, remains a clinically and epidemiologically useful term. However, it is important to recognize that chronic cough and sputum production (chronic bronchitis) is an independent disease entity that may precede or follow the development of airflow limitation and may be associated with development and/or acceleration of fixed airflow limitation. Chronic bronchitis also exists in patients with normal spirometry.⁷

Burden of the Disease

COPD is one of the most important causes of death in most countries. The global burden of disease study projected that COPD, which ranked sixth as a cause of death in 1990, will become the third leading cause of death worldwide by 2020; a newer projection estimated COPD will be the fourth leading cause of death in 2030. This increased mortality is mainly driven by the expanding epidemic of smoking, reduced mortality from other common causes of death (e.g. ischemic heart disease, infectious diseases and aging of the world population).⁷

According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. Most of the information available on COPD prevalence, morbidity and mortality comes from high-income countries. Even in those countries, accurate epidemiologic data on COPD are difficult and expensive to collect. It is known that almost 90% of COPD deaths occur in low- and middle-income countries.⁸

COPD was more common in men, but because of increased tobacco use among women in high-income countries and the higher risk of exposure to indoor air pollution (such as biomass fuel used for cooking and heating) in low-income countries, the disease now affects men and women almost equally.⁸

In 5 years study (1972-1976) 13.6% of patients admitted to shams chest section were COPD suffers.⁹